FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis
Status:
RECRUITING
Trial end date:
2030-12-31
Target enrollment:
Participant gender:
Summary
Try FOLFOX-HAIC combining bevacizumab or cetuximab for initially unresectable colorectal liver metastasis patients to increase the conversion to resection rate to improve long-term survival outcomes